A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer
Study Details
Study Description
Brief Summary
This research is studying the level of oxygen in tumors during the brachytherapy procedure.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Tumors with low levels of oxygen have been found to be more resistant to standard radiation and chemotherapy treatments. For patients with tumors with low oxygen levels, it is not well known if higher radiation doses can overcome treatment resistance to radiation. Currently, there are limited ways of measuring tumor oxygen levels. The investigators believe that measuring tumor oxygen levels during the brachytherapy procedure will allow the investigators to develop better and improved oxygen measurement techniques, and ultimately improve clinical outcomes for patients, such as better local tumor control.
This research study is a Pilot Study, meaning that this is the first time investigators are examining the oxygen sensor being used. This study is designed to test the oxygen sensor's ability to measure the oxygen levels within the participant's cervical tumor with the aid of magnetic resonance imaging (MRI) scans. MRI scans use magnets to make detailed images of the participant's tumor and the surrounding normal tissues during the brachytherapy procedure.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Oxygen Levels in Tumors -Quantitative oxygen measurements will be obtained in a single field of view using T1 sequences |
Outcome Measures
Primary Outcome Measures
- Proportion of patients with a tumor oxygen measurement from at least 1 oxygen sensor catheter [2 years]
Secondary Outcome Measures
- Complete Metabolic Response [2 years]
Absence of abnormal FDG uptake at the site of abnormal FDG uptake noted on the pre-treatment FDG-PET study
- Local Tumor Control [2 years]
Tumor control within the radiation field
- Disease-Specific Survival [2 Years]
From start of treatment to time of disease progression or death
- Overall Survival [2 years]
From start of treatment until death due to any cause
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants must have a biopsy-proven diagnosis of cervical cancer for which interstitial brachytherapy is planned as standard treatment
-
Age 18 years or older
-
ECOG performance status of 2 or less (see Appendix A)
-
Patients who have received prior radiation or chemotherapy may be enrolled on this study
-
Participant is deemed to be an appropriate candidate for MR-guided brachytherapy by the radiation oncologist and the patient elects to be treated with MR-guided brachytherapy
-
Participant provides informed consent for prospective collection of relevant medical records for analysis of clinical outcome and treatment-planning techniques
-
Ability to understand and the willingness to sign a written informed consent document. Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow- up
Exclusion Criteria:
-
Participants who have a contraindication to MRI identified by the MR procedure screening form, such as a pacemaker, aneurysm clip, inner ear implant, neurostimulator, or other non-MR-compatible device or implant
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Brigham and Women's Hospital | Boston | Massachusetts | United States | 02115 |
Sponsors and Collaborators
- Dana-Farber Cancer Institute
Investigators
- Principal Investigator: Martin King, MD, PhD, Brigham and Women's Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 17-596